New Harbinger Publications

Pelago Expands C-Suite with Top Industry Talent to Position Company for Next Phase of Growth

Retrieved on: 
Thursday, January 25, 2024
Telemedicine, Virtual Medicine, Data Management, Other Health, Technology, Audio, Video, Managed Care, Mental Health, General Health, Hospitals, Other Technology, Software, Networks, Internet, Health, Mobile, Wireless, Online, Senior, Psychiatry, Capella University, Addiction, Fertility, Associate, Ziff Davis, Psychotherapy, Opioid, Fintech, Suds, Partnership, Business administration, Oxford University Press, Global Payments, University, Mentorship, Behavior, Bonnier, Acquisition, UCLA, National Geographic, Product management, Master of Business Administration, TSYS, New Harbinger Publications, Cognitive behavioral therapy, Marketing, Dun & Bradstreet, Tobacco, Offers.com, Dun, Engineering, ROI, Management

Additionally, Ed Daley has been promoted to Chief Commercial Officer, and Paige Swanepoel has been promoted to Chief Marketing Officer.

Key Points: 
  • Additionally, Ed Daley has been promoted to Chief Commercial Officer, and Paige Swanepoel has been promoted to Chief Marketing Officer.
  • Dr. Glasner will oversee Pelago’s clinical research programs and ROI validation, and support product development from a clinical perspective.
  • His experience includes business planning, partnership development, and client growth and management as well as building and mentoring high performing teams.
  • Pelago is revolutionizing substance use management and leading the industry with its 3x ROI and 100% fees-at-risk business model, based on validated clinical outcomes and performance metrics.

Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting

Retrieved on: 
Tuesday, October 12, 2021
Company, Twitter, Choroid, NCI, Neoplasm, Inflammation, Technology, Aura, Drug, VDC, Heparin, Acral lentiginous melanoma, Liver, SCS, SC, Physician, List of life sciences, Associate, Radiation, Plaque, ARVO, Mortality, Safety, Stanford University, Industry, Cataract, Publication, MD, Severe cognitive impairment, Society, ASRS, Immune system, New Harbinger Publications, OMF, National, MHS, Randomness, Glaucoma, News, Uveal melanoma, Degenerative disease, Necrosis, Cell membrane, NIH, Eye, Therapeutic index, Patient, National Cancer Institute, Center, Annual general meeting, Pharmaceutical industry, Medical imaging

As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Key Points: 
  • As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
  • Cohorts 1-5 have been fully enrolled (13 patients) and cohort 6 is currently enrolling in the Phase 2 study.
  • The primary objective of the study is to assess safety and efficacy of AU-011 via SC administration for purposes of treating primary indeterminate lesions and choroidal melanoma.
  • Choroidal melanoma is the most common primary intraocular tumor in adults and develops in the uveal tract of the eye.